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Abstract Previously, we showed that cytotoxic T-lym-
phocyte-associated antigen 4 (CTLA-4) is overexpressed in
chronic lymphocytic leukaemia (CLL) and its expression is
correlated with the expression of the major regulators of
G1 phase progression: cyclins D2 and D3, and cyclin-de-
pendent kinase inhibitory protein 1 (p27KIP1). In the pre-
sent study, we blocked CTLA-4 on the surface of both CLL
cells and normal B lymphocytes to investigate the impact
of CTLA-4 on the expression of the mentioned G1 phase
regulators. We found that in CLL patients and in healthy
individuals, the median proportions of cyclin D2-positive
cells as well as cyclin D3? cells significantly decreased
following CTLA-4 blockade. Moreover, CTLA-4 blockade
led to an increase in the median frequencies of p27KIP1-
positive cells, although this increase was marked only in
CLL patients. Our study showed that CTLA-4 affects the
expression of the key regulators of G1 phase progression in
CLL cells as well as in normal B lymphocytes and may
contribute to a better understanding of the role of CTLA-4
in the regulation of G1 phase progression.
Keywords Chronic lymphocytic leukaemia (CLL) 
CTLA-4 (CD152)  Cyclin D2  Cyclin D3  p27KIP1
Introduction
Chronic lymphocytic leukaemia (CLL) is the most com-
mon form of leukaemia in adults in Western Europe and
North America. It has been described as a progressive
accumulation of malignant, morphologically mature
CD19?CD5? cells in the peripheral blood, bone marrow,
and lymphoid organs [1–3]. The disease is characterised
by a highly variable clinical presentation and evolution [4,
5]. Some patients exhibit stable disease over years and
never require a therapeutic intervention, whereas others
progress rapidly towards more advanced stages and suc-
cumb relatively soon despite aggressive treatment. Based
on genetic, phenotypic, and molecular characteristics of
CLL, several prognostic markers have emerged in the past
decade [6, 7]. It has been well documented that the high-
risk phenotype is typically associated with unmutated
immunoglobulin heavy variable genes (IgVH) [8], high
expression of the CD38 surface marker [9], or the f-chain-
associated protein 70 kDa (ZAP-70) [10], as well as with
chromosomal aberrations such as 17p (the site of tumour
protein p53) or 11q23 deletions (the site of ataxia te-
langiectasia mutated ATM) [11]. Recently, it has been
postulated that the difference in clinical course among
CLL patients may, at least in part, be determined by the
proliferative capacity of CLL cells [12, 13]. It is be-
coming increasingly evident that the cells located in the
proliferation centres (PCs) of lymph nodes and bone
marrow proliferate more than previously anticipated [13],
and CLL patients with higher birth rates are much more
likely to exhibit active or to develop progressive disease
than those with lower birth rates [13]. Moreover, the
proliferating cells in PCs represent the CLL proliferating
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In contrast to the proliferating cells in PCs, the vast
majority of CLL cells circulating in the peripheral blood
are arrested in the G0/early G1 phase of the cell cycle. The
key regulators of G1 phase progression in human T and B
lymphocytes are the D-type cyclins cyclin D2 and D3, and
p27KIP1 (cyclin-dependent kinase inhibitory protein 1). The
D-type cyclins positively regulate passage through the G1
phase by binding to and stimulating the activities of their
catalytic partners, the cyclin-dependent kinases (CDKs)
cdk4 and cdk6 [14–17], while p27KIP1 exerts an inhibitory
effect on the kinases cdk4 and cdk6 or their complexes
with cyclin D2 or cyclin D3 [17–19]. Moreover, one of the
factors involved in regulation of cell cycle progression of T
cells is cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4; CD152) [20, 21]. It has been well documented
that CTLA-4 prolongs the progression of T cells through
the G1 phase by influencing the expression of the major
regulators of this cell cycle phase [20, 21]. CTLA-4 up-
regulates the expression of cyclin D2 and inhibits cyclin
D3, cdk4, and cdk6 production in these cells. Furthermore,
CTLA-4 affects the degradation of p27KIP1 protein and
contributes to its earlier and stronger re-expression during
the late stages of T cell activation [20, 21]. In contrast to
the well-documented involvement of CTLA-4 in the
regulation of cell cycle progression in T cells [20, 21], only
limited information is known about the role of this protein
in cell cycle progression in normal B cells and malignant B
lymphocytes. Our previous study indicated that CTLA-4 is
overexpressed in freshly drawn CLL cells and it may be
involved in the regulation of G1 phase progression in these
cells [22]. We found that CTLA-4 expression positively
correlated with both cyclin D2 and p27KIP1 expression and
negatively with cyclin D3 level. Moreover, CTLA-4 ex-
pression positively correlated with the percentage of leu-
kaemic cells in G0/G1 phase. Here, we have extended our
previous study to examine whether stimulation with
DSP30, a CpG oligodeoxynucleotide (ODN), and rIL-2
influences CTLA-4 expression in CLL cells. The main aim
of this study was to investigate whether the CTLA-4
molecule affects the expression of cell cycle regulators of
G0/G1 phase. For that purpose, we blocked CTLA-4 on the
surface of CLL cells using monoclonal anti-CTLA-4 anti-
bodies to assess the expression of cyclins D2 and D3, and
p27KIP1 protein. To the best of our knowledge, such studies
are lacking so far.
Materials and methods
Patients and healthy donors
The study design was approved by the local Bioethical
Committee at the Medical University of Wroclaw, Poland,
and is in accordance with the Helsinki Declaration of 1975.
All participants gave written informed consent after the
purpose of the study was explained to them. Thirty-eight
previously untreated CLL patients of the Clinic of Hae-
matology, Blood Neoplasms, and Bone Marrow Trans-
plantation, Wroclaw Medical University, Poland, were
enrolled in this study. In each of them, the diagnosis was
established according to generally accepted criteria in-
cluding absolute peripheral blood lymphocytosis
C5 9 109/L and the co-expression of CD5, CD19, and
CD23 antigens on malignant cells. The disease stages were
determined according to the Rai classification. Clinical and
laboratory features are presented in Table 1.
Leucocyte-enriched fractions of peripheral blood do-
nated by 15 healthy volunteers matched for age and sex
with the CLL patients were purchased from the Regional
Centre of Blood Donation and Treatment in Wroclaw,
Poland.
Cell isolation and separation procedures
Peripheral blood mononuclear cells (PBMCs) were
separated from heparinised freshly drawn peripheral ve-
nous blood of CLL patients and healthy controls by
buoyant density-gradient centrifugation on Lymphoflot
(Bio-Rad Medical Diagnostics GmbH, Dreieich, Germany)
and washed three times in phosphate-buffered saline (PBS)
(without Ca2? and Mg2?). The PBMCs were suspended in
95 % foetal calf serum (CytoGen GmbH, Sinn, Germany)
Table 1 Clinical characteristics of CLL patients
Characteristics Value
Number of patients 38
Gender (female/male) 15/23







WBC count (1 9 109/l) 72.2 ± 98.4
Lymphocyte count (1 9 109/l) 66.5 ± 96.8
Hb level (g/dl) 12.9 ± 1.9
Platelet count (1 9 109/l) 135.2 ± 55.1
LDH (U/l) 206.8 ± 55.3
b2-microglobulin (mg/l) 3.3 ± 1.4
For age and clinical parameters, the mean values and standard de-
viation (SD) were presented
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containing 5 % DMSO (Sigma-Aldrich, St. Gallen,
Switzerland) and stored in liquid nitrogen until used.
CLL cells were isolated from PBMCs by negative se-
lection using EasySep Human B Cell Enrichment Kit
without CD43 Depletion (STEMCELL Technologies Inc,
Vancouver, Canada) according to the manufacturer’s in-
structions. Following this separation procedure, more than
98 % of the resulting cell population was CD19?CD5? as
assessed by flow cytometry using anti-CD19 and anti-CD5
monoclonal antibodies (mAbs) (Becton–Dickinson, BD
Biosciences, San Diego, USA). Normal B cells from
healthy individuals were isolated from PBMCs by negative
selection using EasySep Human B Cell Enrichment Kit
(STEMCELL Technologies Inc, Vancouver, Canada) ac-
cording to the manufacturer’s instructions, achieving above
98 % purity as assessed by flow cytometry using anti-
CD19 mAb.
Culture conditions
Purified normal CD19? lymphocytes or CLL cells were
suspended at 1 9 106 cells/ml in RPMI-1640 medium
(Gibco, Paisley, UK) supplemented with 10 % foetal calf
serum (CytoGen GmbH, Sinn, Germany), 2 mmol/l L-g-
lutamine and 50 lg/ml gentamycin (KRKA-Poland, War-
saw, Poland), and cultured using 24-well U-bottom culture
plates (Nunc GmbH & Co. KG, Langenselbold, Germany)
at 37 C in a 5 % CO2 humidified atmosphere for 24 and
72 h either in medium alone or together with 1 lM DSP30
(50-TCGTCGCTGTCTCCGCTTCTTCTTGCC-30) (TIB
MOLBIOL, Berlin, Germany) [23] and 100 U/ml rIL-2
(Eurocetus, Amsterdam, The Netherlands) [24]. For the
blocking experiment, purified CLL cells and normal
CD19? lymphocytes were cultured with 1 lM DSP30 and
100 U/ml IL-2 with the blocking anti-CTLA-4 mAbs
(50 lg/ml) (BD Pharmingen, BD Biosciences, San Diego,
USA) [25] or control IgG2 (50 lg/ml) (BD Pharmingen,
BD Biosciences, San Diego, USA).
Immunostaining of CTLA-4 and cell cycle
regulators of G0/G1 phase, and flow cytometric
analysis
The expression of these molecules was studied in purified
CLL cells and normal CD19? lymphocytes before and after
24 and 72 h culture by a single immunostaining method.
Briefly, for detection of surface expression of the
CTLA-4 molecule, the cells were washed twice in PBS
(without Ca2? and Mg2?), divided into tubes at a con-
centration of 5 9 105 cells per tube and incubated with
anti-CTLA-4 (CD152)/RPE mAbs (BD Pharmingen, BD
Biosciences, San Diego, USA) for 30 min at 4 C in the
dark. Excess unbound antibodies were removed by two
washes with PBS. Following these washes, the cells were
resuspended in PBS and analysed by flow cytometry using
a FACSCalibur flow cytometer (Becton–Dickinson, BD
Biosciences, San Diego, USA). For determination of in-
tracellular CTLA-4 expression, the cells were first fixed for
10 min at room temperature in 2 % paraformaldehyde
(Fluka, Sigma-Aldrich, Buchs, Germany), washed in PBS,
and incubated for 10 min at room temperature in BD
Permeabilizing Solution 2 (Becton–Dickinson, BD Bio-
sciences, San Diego, USA) according to the manufacturer’s
instructions. Then, the cells were incubated with anti-
CTLA-4 (CD152)/RPE mAbs for 30 min at 37 C in the
dark.
For detection of cyclins D2 and D3, and p27KIP1 protein,
the cells were fixed, permeabilised, and stained with anti-
cyclin D2/FITC, anti-p27KIP1/FITC mAbs (Santa Cruz
Biotechnology, Inc, Heidelberg, Germany), and anti-cyclin
D3/FITC mAb (BD Pharmingen, BD Biosciences, San
Diego, USA) according to the manufacturer’s instructions.
Negative controls were always done by omitting the
mAbs and by incubating the cells with mouse Ig of the same
isotype as the mAbs conjugated with RPE or FITC. At least,
10,000 events per sample were analysed. The results were
expressed as the proportion of CTLA-4-, cyclin D2-, cyclin
D3-, or p27KIP1-positive cells. The CellQuest program was
used for statistical analysis of the acquired data.
Statistical analysis
Statistical analyses of the clinical data and laboratory
findings were conducted using Statistica 10.0 or PQStat
software. For clinical parameters, the mean values and
standard deviation were calculated. For all other analysed
variables, the median values and 25th and 75th interquar-
tile range were calculated. All collected data were exam-
ined for normal distribution and for homogeneity of
variances using the Shapiro–Wilk test and Levene’s test,
respectively. If data were normally distributed and had
homogeneous variances, the comparisons between the
studied groups were performed using the Student t test for
independent samples. If data were not normally distributed
and/or had heterogeneous variances, the nonparametric
Mann–Whitney U test was used. To test the effects of
culture and CTLA-4 blockade on analysed variables, the
repeated measures ANOVA and the Student t test for de-
pendent samples were used. If data were not normally
distributed and/or had heterogeneous variances, the Fried-
man ANOVA test followed by a post hoc test (Dunn test),
and the nonparametric Wilcoxon signed-rank test were
applied. The relationship between the clinical parameters
and CTLA-4 expression was tested with Spearman’ rank
correlation coefficient. In all analyses, differences were
considered significant when P B 0.05.
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Results
Expression of CTLA-4 molecule and cell cycle
regulators of G0/G1 phase in freshly drawn CLL
cells and normal CD191 lymphocytes
Since CTLA-4 is transiently expressed on the cell surface
and is predominantly located in intracellular compart-
ments due to constitutive internalisation from the plasma
membrane [26], we determined both surface and intra-
cellular expression of this molecule. Similarly, to our
earlier study [22], we observed significantly higher me-
dian proportions of leukaemic cells co-expressing the
CTLA-4 molecule on the surface (sCTLA-4) as well as in
cytoplasmic compartments (cCTLA-4) in CLL patients
compared to the median percentages of the corresponding
cells in healthy individuals (Table 2). Moreover, as we
previously showed [22], the frequencies of both the
sCTLA-4-positive and cCTLA-4-positive CLL cells were
very variable in the studied patients, ranging from 3.5 to
57.1 % and from 10.1 to 74.1 %, respectively. Further-
more, we found negative correlations between sCTLA-4
as well as cCTLA-4 expression in leukaemic cells and the
following clinical parameters: Rai stage (r = -0.46,
P = 0.01 and r = -0.43, P = 0.02), leucocyte count
(r = -0.48, P = 0.009 and r = -0.66, P = 0.0002), and
lymphocyte count (r = -0.45, P = 0.02 and r = -0.64,
P = 0.0003) (Fig. 1).
As regards cell cycle regulators of G0/G1 phase, we
observed significantly higher median proportions of both
cyclin D2-positive and p27KIP1-positive cells in the CLL
group compared to the median percentages of the corre-
sponding cells in healthy volunteers (Table 3). In contrast,
the median frequency of cyclin D3? cells in CLL patients
was markedly lower compared to healthy controls
(Table 3).
Expression of CTLA-4 molecule in DSP301rIL-2-
stimulated CLL lymphocytes and normal CD191
cells
We found a significant impact of the cell culture in medium
alone as well as ex vivo stimulation with DSP30?rIL-2 on
the surface and intracellular expression of the CTLA-4
molecule in both CLL patients and healthy individuals. As
regards surface expression, in CLL patients as well as in
healthy individuals, a marked decrease in the median
proportions of sCTLA-4-positive cells after 72 h of cell
culture in medium alone was found (Table 2; Figs. 2, 3).
Consequently, the median percentage of sCTLA-4? cells in
CLL patients remained higher than in healthy volunteers
only after 24 h of culture (Table 2). In CLL patients,
ex vivo stimulation led to a significant decrease in the
median percentage of sCTLA-4? cells after 24 h of culture
(Table 2; Figs. 2, 3). In contrast, in healthy volunteers,
stimulation with DSP30?rIL-2 resulted in an increase in
the median frequencies of sCTLA-4-positive lymphocytes
compared to the control culture, although the differences
were statistically significant only after 72 h of culture
(Table 2; Figs. 2, 3). Moreover, no significant differences
in the median proportions of sCTLA-4? cells between CLL
patients and healthy individuals following ex vivo
stimulation were found (Table 2).
As regards cCTLA-4 expression, in CLL patients as well
as in healthy individuals, a significant decrease in the
median proportions of cCTLA-4-positive cells after 72 h of
cell culture in medium alone was found (Table 2; Figs. 2,
4). Moreover, after 72 h of ex vivo stimulation, the median
percentages of cCTLA-4? cells in both studied groups
were significantly higher compared to the control culture
(Table 2; Figs. 2, 4). Of note, the median proportions of
cCTLA-4-positive cells in CLL patients remained higher
than in healthy controls at each time point tested (Table 2).
Table 2 Median proportions and 25th–75th interquartile range of CLL cells and normal B lymphocytes co-expressing CTLA-4 molecule
Groups Unstimulated 24-h culture 72-h culture
Medium alone DSP30?rIL-2 Medium alone DSP30?rIL-2
% sCTLA-4-positive cells
CLL patients (n = 38) 32.8 (22.9–44.6) 28.6 (22.8–37.5) 25.8 (22.0–29.1) 18.2 (13.9–25.0) 17.7 (12.9–26.3)
Controls (n = 15) 18.8 (17.9–20.1) 17.9 (11.4–24.9) 20.9 (13.2–28.5) 11.8 (5.6–14.9) 14.8 (11.1–24.5)
CLL patients versus controls P = 0.001 P = 0.03 NS NS NS
% cCTLA-4-positive cells
CLL patients (n = 38) 43.8 (23.6–59.4) 51.0 (42.7–59.1) 52.1 (42.3–60.3) 42.4 (28.8–51.8) 44.7 (36.4–60.2)
Controls (n = 15) 25.7 (8.7–33.1) 30.4 (23.0–37.3) 26.2 (21.3–40.4) 14.1 (9.6–21.3) 19.1 (4.5–27.0)
CLL patients versus controls P = 0.004 P = 0.002 P = 0.0005 P = 0.0008 P = 0.000009
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Expression of cell cycle regulators of G0/G1 phase
in DSP301rIL-2-stimulated CLL lymphocytes
and normal CD191 cells
Simultaneously with CTLA-4 expression, we analysed the
expression of cell cycle regulators of G0/G1 phase. As
regards cyclin D2 expression, culture in medium alone
resulted in a marked decrease in the median percentage of
cyclin D2-positive cells after 72 h of culture in CLL pa-
tients (Table 3; Fig. 5). In contrast, in healthy individuals,
the median proportions of CD19? cyclin D2? lymphocytes
maintained stable during the control culture (Fig. 5). In
consequence, the median frequency of cyclin D2-positive
cells in CLL patients remained significantly higher than in
Fig. 1 Correlation between CTLA-4 expression and clinical pa-
rameters. a Negative association between proportions of sCTLA-4-
positive leukaemic cells and Rai stages. b Negative correlation
between percentages of cCTLA-4-positive leukaemic cells and Rai
stages. c Negative association between frequencies of sCTLA-4-
positive leukaemic cells and leucocyte count. d Negative correlation
between percentages of cCTLA-4-positive leukaemic cells and
leucocyte count. e Negative association between proportions of
sCTLA-4-positive leukaemic cells and lymphocyte count. f Negative
correlation between frequencies of cCTLA-4-positive leukaemic cells
and lymphocyte count
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Table 3 Median proportions and 25th–75th interquartile range of CLL cells and normal B lymphocytes co-expressing cyclin D2, cyclin D3, and
p27KIP1
Groups Unstimulated 24-h culture 72-h culture
Medium alone DSP30?rIL-2 Medium alone DSP30?rIL-2
% cyclin D2-positive cells
CLL patients (n = 38) 37.7 (26.5–52.9) 38.1 (16.4–52.4) 31.9 (13.4–52.5) 0.0 (0.0–23.5) 3.2 (0.0–10.5)
Controls (n = 15) 0.0 (0.0–14.2) 9.9 (7.3–14.2) 64.6 (43.2–75.3) 1.8 (0.0–8.1) 0.9 (0.0–36.6)
CLL patients versus controls P = 0.004 P = 0.009 NS NS NS
% cyclin D3-positive cells
CLL patients (n = 38) 53.2 (44.2–61.8) 51.5 (44.8–61.0) 54.9 (48.3–65.7) 35.8 (30.2–48.5) 38.5 (26.5–47.8)
Controls (n = 15) 64.4 (56.4–84.5) 65.5 (57.7–66.9) 77.3 (76.3–84.5) 51.9 (41.1–62.6) 56.9 (51.7–65.7)
CLL patients versus controls P = 0.01 P = 0.01 P = 0.00001 NS P = 0.0004
% p27KIP1-positive cells
CLL patients (n = 38) 81.4 (69.2–87.3) 85.5 (75.1–91.3) 68.9 (46.1–80.4) 84.5 (7.4–91.2) 51.2 (37.9–66.5)
Controls (n = 15) 51.5 (28.4–65.4) 58.5 (21.1–77.4) 27.7 (7.9–58.5) 32.5 (16.0–40.2) 23.7 (7.4–36.0)
CLL patients versus controls P = 0.00007 P = 0.0002 P = 0.0009 P = 0.000001 P = 0.0001
Fig. 2 Surface and intracellular expression of CTLA-4 in leukaemic cells and normal B lymphocytes before and after cell culture. Boxes and
whiskers 25th–75th interquartile range and minimum–maximum, respectively; the median is the central line in each box
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healthy controls only after 24 h of control culture
(Table 3). Moreover, in CLL patients, ex vivo stimulation
led to a significant decline in the median proportion of the
cyclin D2? cells after 72 h of cell culture compared to the
value after 24 h of culture (Fig. 5). In contrast, in healthy
individuals, after 24 h of ex vivo stimulation, we observed
a marked increase in the median percentage of CD19?
cyclin D2? cells (Fig. 5). Moreover, after 72 h of ex vivo
stimulation, the median proportion of cyclin D2-positive
cells markedly decreased compared to the value after 24 h
of culture (Fig. 5). Furthermore, no significant differences
in the median percentages of cyclin D2? cells between
CLL patients and healthy individuals following ex vivo
stimulation were found (Table 3).
As regards cyclin D3 expression, culture in medium
alone resulted in a marked decrease in the median per-
centage of cyclin D3-positive cells after 72 h in CLL pa-
tients as well as in healthy volunteers (Table 3; Fig. 5).
Fig. 3 Representative
examples of flow cytometric
analyses of surface expression
of CTLA-4 (sCTLA-4) on
leukaemic cells (a) and normal
B lymphocytes (b) before and
after cell culture in medium
alone and under stimulating
conditions (DSP30?rIL-2).
Numbers on dot plots represent
the percentage of leukaemic or
normal B lymphocytes
expressing CTLA-4 on the cell
surface
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Moreover, the median percentage of cyclin D3? cells in
CLL patients remained markedly lower than in healthy
volunteers only after 24 h of control culture (Table 3). In
both studied groups, after 24 h of ex vivo stimulation, we
observed a significant increase in the median proportions of
cyclin D3? cells (Fig. 5). Moreover, in CLL patients as
well as in healthy individuals, the median frequencies of
cyclin D3-positive cells decreased markedly after 72 h of
stimulating culture compared to the corresponding cells
after 24 h of ex vivo stimulation (Fig. 5). Furthermore, in
CLL patients, the median proportions of cyclin D3-positive
cells were markedly lower compared with healthy volun-
teers under stimulation conditions.
As regards p27KIP1 expression, in both studied groups,
no significant impact of the culture in medium alone on the
expression of this protein was found (Table 3; Fig. 5). In
Fig. 4 Representative
examples of flow cytometric
analyses of intracellular
expression of CTLA-4 (cCTLA-
4) in leukaemic cells (a) and
normal B lymphocytes
(b) before and after cell culture
in medium alone and under
stimulating conditions
(DSP30?rIL-2). Numbers on
dot plots represent the
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CLL patients, ex vivo stimulation led to a gradual decrease
in the median frequencies of p27KIP1-positive cells with the
minimum values after 72 h of culture. Likewise, in healthy
individuals, the median percentages of CD19?p27KIP1?
cells gradually declined under stimulation conditions and
reached a minimum level after 72 h, but these decreases
were not statistically significant. Moreover, the median
frequencies of p27KIP1-positive cells in CLL patients re-
mained markedly higher compared with healthy volunteers
at each time point tested (Table 3).
Fig. 5 Cyclins D2 and D3, and
p27KIP1 expression in leukaemic
cells and normal B lymphocytes
before and after cell culture.
Boxes and whiskers 25th–75th
interquartile range and
minimum–maximum,
respectively; the median is the
central line in each box
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Effect of CTLA-4 blockade on expression of cell
cycle regulators of G0/G1 phase in CLL
lymphocytes and normal CD191 cells
We next examined whether blocking CTLA-4 on the cell
surface would affect the expression of the key regulators of
G0/G1 phase. We observed a significant impact of CTLA-4
blockade on the expression of cell cycle regulators of G0/
G1 phase in CLL patients as well as in healthy individuals.
As regards cyclin D2, in both studied groups, we observed
a marked decrease in the median proportions of cyclin D2-
positive cells after 24 h of blocking culture (Figs. 6, 7, 8).
Moreover, no significant differences in the median per-
centages of cyclin D2? cells between CLL patients and
healthy individuals were found.
As regards cyclin D3 expression, after 24 h of blocking
culture, in CLL patients, we observed a marked decrease in
the median proportions of cyclin D3-positive cells (Figs. 6,
7). In healthy volunteers, CTLA-4 blockade led to a de-
crease in CD19? cyclin D3? cells after 24 and 72 h of
culture (Figs. 6, 8). Moreover, in CLL patients and in
healthy individuals, after 72 h of CTLA-4 blocking culture,
the median frequencies of cyclin D3-positive cells were
markedly lower compared to corresponding cells after 24 h
of culture (Figs. 6, 7, 8). Furthermore, the median fre-
quencies of cyclin D3-positive leukaemic cells in CLL
patients were markedly lower compared with healthy vol-
unteers at each time point tested (P = 0.00002 and 0.005
after 24 and 72 h of blocking culture, respectively).
As regards p27KIP1 expression, in CLL patients, CTLA-
4 blockade resulted in an increase in the median propor-
tions of p27KIP1-positive cells compared to corresponding
cells under stimulating conditions, although this increase
was statistically significant only after 24 h of blocking
culture (Figs. 6, 7). Moreover, in CLL patients, after 72 h
of CTLA-4 blocking culture, the median frequency of
p27KIP1? cells was markedly lower compared to corre-
sponding cells after 24 h of culture (Figs. 6, 7). In healthy
individuals, an increase in the median proportions of
p27KIP1-positive lymphocytes following 24 and 72 h of
blocking culture was observed, although this increase was
not statistically significant (Figs. 6, 8). Moreover, the me-
dian frequency of p27KIP1-positive cells in CLL patients
remained markedly higher compared with healthy indi-
viduals at each time point tested (P = 0.000005 and 0.003
after 24 and 72 h of blocking culture, respectively).
Discussion
In the present study, we confirmed our earlier observations
[22] that both the surface and cytoplasmic expression of the
CTLA-4 molecule is overexpressed in freshly isolated
peripheral blood CLL cells. This finding raises a question
about the mechanisms underlying the elevated levels of
CTLA-4 expression in CLL cells. Since CTLA-4 expres-
sion is transiently inducible during T and B activation [27,
28] and it is considered to be an activation marker, the
higher expression of CTLA-4 in CLL cells may reflect the
systemic activation status in the periphery in CLL patients.
It has been well documented that CLL cells receive many
growth-promoting signals [29–31], which are mediated by
receptors constitutively expressed on the subset of neo-
plastic B cells [32, 33]. In addition, literature data confirm
that CLL cells bear the phenotype of activated B cells
based on overexpression of the classical activation markers
CD23, CD25, CD69 and CD71, and under-expression of
CD22, Fcc IIb, CD79b, and immunoglobulin D, which are
down-regulated by cell triggering and activation [34]. The
suggestion that CLL cells may be in a partial state of ac-
tivation also results from the observation of cyclin D2
expression, which is induced during cell stimulation by
growth factors in early G0 phase. Accordingly, in the
current study, we confirmed our previous observations [22,
35, 36] that the median proportion of freshly isolated CLL
cells co-expressing cyclin D2 was markedly higher than
that observed in normal B lymphocytes. Furthermore,
based on the fact that CTLA-4 gene polymorphisms may
influence the CTLA-4 expression level in CLL cells [22,
37], we cannot exclude that the strong divergence of
CTLA-4 expression observed among the patients might
result, at least in part, from the presence of specific alleles
predisposing to overexpression of the CTLA-4 molecule.
We also found a negative correlation between CTLA-4
expression in CLL cells and the clinical parameters such as
Rai stage and leucocyte as well as lymphocyte count. This
finding is consistent with the study of Joshi et al. [38]
showing that the level of CTLA-4 gene expression in CLL
cells predicts clinical outcome of CLL patients; lower ex-
pression of CTLA-4 is associated with significantly shorter
time to treatment and poor prognosis compared with high
CTLA-4 expression associated with good clinical outcome.
In the present study, we showed for the first time the
impact of ex vivo specific stimulation of CLL cells with
DSP30 (CpG ODN)?rIL-2 on CTLA-4 expression. An
assessment of CTLA-4 expression under this stimulation
condition seems to have clinical relevance in the context of
the discussion about using CpG ODNs as therapeutic
agents in CLL patients [39]. We found that ex vivo
stimulation led to a significant decrease in the median
proportion of CLL cells expressing the CTLA-4 molecule
on their surface, which became comparable to the value of
the corresponding cells in healthy individuals. In contrast,
the intracellular expression of this protein in leukaemic
cells markedly increased after 72 h of cell culture in the
presence of DSP30 and rIL-2 and remained significantly
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Fig. 6 Effect of CTLA-4
blockade on the expression of
cyclins D2 and D3, and p27KIP1
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higher than in healthy volunteers. This observation seems
to suggest that the down-regulation of sCTLA-4 expression
upon stimulation may result from disturbed recycling of the
CTLA-4 molecule to the cell surface in CLL. Moreover, as
higher expression of the CTLA-4 gene is associated with
good clinical outcome [38], application of CpG ODN that
reduces the surface expression of CTLA-4 in leukaemic
cells as a therapeutic agent may not be beneficial for CLL
patients.
Literature data show that ex vivo stimulation with CpG
ODN results in down-regulation of p27KIP1 expression and
up-regulated expression of cyclins D2 and D3 in CLL cells
and normal B lymphocytes [40–43]. In the present study,
we also observed the down-regulation of p27KIP1 expres-
sion following ex vivo stimulation in CLL patients as well
as in healthy volunteers. Of note, in spite of the decrease in
p27KIP1 expression in both studied groups, the median
frequencies of p27KIP1-positive cells in CLL patients re-
mained significantly higher compared with healthy indi-
viduals at each time point tested. It is noteworthy that high
expression of this protein is associated with poorer out-
come of CLL [44–46]. As regards cyclin D2, in contrast to
others [40–42], after 24 h of stimulating culture, we did not
observe up-regulation of cyclin D2 expression in CLL
cells. This discrepancy might result from the different ex-
perimental procedures used. We estimated the expression
of these proteins as the proportions of CLL cells co-ex-
pressing several proteins using flow cytometry, whereas the
authors of the contradictory reports examined the protein
expression by western blot analysis. Due to cyclin D2 be-
ing overexpressed in freshly drawn CLL cells compared to
normal B lymphocytes [22, 35, 36, 47] and maintained at
similar high levels in CLL cells after 24 h of ex vivo
stimulation, the median percentage of cyclin D2-positive
cells in CLL patients was comparable to the corresponding
cells in healthy individuals, in which up-regulation of cy-
clin D2 expression was observed. Moreover, in agreement
with literature data [40–43], we found a significant increase
in the median percentages of cyclin D3-positive cells after
24 h of ex vivo stimulation in CLL patients as well as in
healthy volunteers. Of note, the median proportions of CLL
cells co-expressing cyclin D3 remained markedly lower at
each time point tested compared to corresponding cells in
healthy individuals. To elucidate this phenomenon, further
studies are necessary.
One of the main aims of this study was to examine
whether the CTLA-4 molecule is able to influence the
expression of the key regulators of G0/G1 phase in CLL
cells as well as normal B lymphocytes. Our previous data
[22] indicated that expression of the CTLA-4 molecule in
CLL cells correlated with the expression of the G0/G1
phase regulators cyclins D2 and D3, and p27KIP1, sug-
gesting the impact of CTLA-4 on prolonging the G1 phase
in leukaemic lymphocytes. In the present study, we ex-
amined the expression of the mentioned cell cycle
regulators following blockade of CTLA-4 on the surface of
CLL cells as well as normal B lymphocytes. Blocking
CTLA-4 on the surface of the studied cells is a useful
method in research to elucidate the function of this protein.
We found that CTLA-4 blockade did affect the expression
of studied regulators of G0/G1 phase. In particular, we
observed for the first time a significant decrease in the
median proportions of both cyclin D2- and cyclin D3-
positive cells in CLL cells as well as in normal B lym-
phocytes following 24 h of blocking culture. Moreover, we
noted that CTLA-4 blockade led to an increase in the
median proportions of p27KIP1-positive cells after 24 h of
culture in CLL cells as well as in normal B lymphocytes,
although this increase was statistically significant only in
the group of CLL patients. What are the possible
mechanisms responsible for this phenomenon? It has been
shown that the expression of D-type cyclins and p27KIP1
protein stability is controlled by PI3 K (phosphatidyli-
nositol 3-kinase)-related pathways [48, 49]. Activation of
PI3 K-mediated pathways leads to transcription of D-type
cyclins and to reduction of the p27KIP1 protein level [48,
49]. In some experimental systems, it has been shown that
CTLA-4 engagement on T cells activates PI3K [50]. As
CTLA-4 blockade has an opposite effect, it seems highly
probable that CTLA-4 blockade may lead to inactivation of
PI3K-related pathways. Based on this hypothesis, we can
speculate that blockade of CTLA-4 on CLL cells as well as
on normal B lymphocytes may lead to inactivation of
PI3K-related pathways, resulting in decreased expression
of cyclins D2 and D3, and accumulation of p27KIP1 protein,
in consequence. Further studies are required to confirm a
direct relationship between CTLA-4, PI3K-related path-
ways, and the expression of the mentioned cell cycle
regulators of G0/G1 phase.
Furthermore, an interesting finding was that the median
proportions of cyclin D2-positive cells in CLL patients and
healthy volunteers were comparable following CTLA-4
blockade, whereas the median percentages of cyclin D3?
and of p27KIP1? leukaemic cells remained lower and
higher, respectively, than in healthy individuals. Further
investigations are needed to explain this phenomenon.
Extending our previous study, we have demonstrated by
blocking experiments that the CTLA-4 molecule influences
the expression of the key regulators of G0/G1 phase—
cyclins D2 and D3, and p27KIP1—in both malignant and
bFig. 7 Representative examples of flow cytometric analysis of the
effect of CTLA-4 blockade on expression of G0/G1 phase regulators
in leukaemic cells after 24 h (a) and 72 h (b) of blocking culture.
Numbers on dot plots represent the percentage of leukaemic cells
expressing cyclin D2, cyclin D3 or p27KIP1
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normal B lymphocytes. We also confirmed the recent ob-
servation that CTLA-4 expression in peripheral blood CLL
cells negatively correlates with disease progression, sug-
gesting its clinical relevance as a prognostic marker. Since
CTLA-4, cyclin D2 and p27KIP1 seem to have prognostic
significance in CLL, further studies are necessary to elu-
cidate the molecular mechanisms of the relationship be-
tween these proteins.
Acknowledgments This work was supported by a grant from the
National Science Centre (Poland, Project Number: N N402 284936).
Conflict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leuke-
mia. N Engl J Med. 2005;352(8):804–15. doi:10.1056/NEJMra0
41720.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero
G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR,
Kipps TJ. Guidelines for the diagnosis and treatment of chronic
lymphocytic leukemia: a report from the International Workshop
on chronic lymphocytic leukemia updating the National Cancer
Institute-Working Group 1996 guidelines. Blood. 2008;111(12):
5446–56. doi:10.1182/blood-2007-06-093906.
3. Caligaris-Cappio F, Ghia P. The normal counterpart to the
chronic lymphocytic leukemia B cell. Best Pract Res Clin Hae-
matol. 2007;20(3):385–97. doi:10.1016/j.beha.2007.02.005.
4. Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified
approach to therapy in chronic lymphocytic leukemia. Best Pract
Res Clin Haematol. 2007;20(3):439–53. doi:10.1016/j.beha.2007.
02.006.
5. Hamblin TJ, Oscier DG. Chronic lymphocytic leukaemia: the
nature of the leukaemic cell. Blood Rev. 1997;11(3):119–28.
doi:10.1016/j.beha.2007.02.001.
6. Chiorazzi N. Implications of new prognostic markers in chronic
lymphocytic leukemia. Hematol Am Soc Hematol Educ Program.
2012;2012:76–87. doi:10.1182/asheducation-2012.1.76.
7. Hamblin TJ. Prognostic markers in chronic lymphocytic leukae-
mia. Best Pract Res Clin Haematol. 2007;20(3):455–68. doi:10.
1016/j.beha.2007.02.001.
8. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK.
Unmutated Ig V(H) genes are associated with a more aggressive
form of chronic lymphocytic leukemia. Blood. 1999;94(6):
1848–54.
9. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL,
Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM,
Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N.
Ig V gene mutation status and CD38 expression as novel prog-
nostic indicators in chronic lymphocytic leukemia. Blood.
1999;94(6):1840–7.
10. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D,
Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat
E. ZAP-70 expression as a surrogate for immunoglobulin-vari-
able-region mutations in chronic lymphocytic leukemia. N Engl J
Med. 2003;348(18):1764–75. doi:10.1056/NEJMoa023143.
11. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A,
Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations
and survival in chronic lymphocytic leukemia. N Engl J Med.
2000;343(26):1910–6. doi:10.1056/NEJM200012283432602.
12. Chiorazzi N. Cell proliferation and death: forgotten features of
chronic lymphocytic leukemia B cells. Best Pract Res Clin
Haematol. 2007;20(3):399–413. doi:10.1016/j.beha.2007.03.007.
13. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar
D, Murphy EJ, Koduru P, Ferrarini M, Zupo S, Cutrona G, Damle
RN, Wasil T, Rai KR, Hellerstein MK, Chiorazzi N. In vivo
measurements document the dynamic cellular kinetics of chronic
lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755–
64. doi:10.1172/JCI23409.
14. Ajchenbaum F, Ando K, DeCaprio JA, Griffin JD. Independent
regulation of human D-type cyclin gene expression during G1 phase
in primary human T lymphocytes. J Biol Chem. 1993;268(6):4113–9.
15. Parada Y, Banerji L, Glassford J, Lea NC, Collado M, Rivas C,
Lewis JL, Gordon MY, Thomas NS, Lam EW. BCR-ABL and in-
terleukin 3 promote haematopoietic cell proliferation and survival
through modulation of cyclin D2 and p27Kip1 expression. J Biol
Chem. 2001;276(26):23572–80. doi:10.1074/jbc.M101885200.
16. Solvason N, Wu WW, Parry D, Mahony D, Lam EW, Glassford
J, Klaus GG, Sicinski P, Weinberg R, Liu YJ, Howard M, Lees E.
Cyclin D2 is essential for BCR-mediated proliferation and CD5 B
cell development. Int Immunol. 2000;12(5):631–8.
17. Wagner EF, Hleb M, Hanna N, Sharma S. A pivotal role of cyclin
D3 and cyclin-dependent kinase inhibitor p27 in the regulation of
IL-2-, IL-4-, or IL-10-mediated human B cell proliferation.
J Immunol. 1998;161(3):1123–31.
18. Boonen GJ, van Dijk AM, Verdonck LF, van Lier RA, Rijksen G,
Medema RH. CD28 induces cell cycle progression by IL-2-in-
dependent down-regulation of p27kip1 expression in human pe-
ripheral T lymphocytes. Eur J Immunol. 1999;29(3):789–98.
doi:10.1002/(SICI)1521-4141(199903)29:03\789:AID-
IMMU789[3.0.CO;2-5.
19. Mohapatra S, Agrawal D, Pledger WJ. p27Kip1 regulates T cell
proliferation. J Biol Chem. 2001;276(24):21976–83. doi:10.1074/
jbc.M009788200.
20. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Al-
lison JP. CTLA-4-mediated inhibition of early events of T cell
proliferation. J Immunol. 1999;162(10):5813–20.
21. Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A,
Mandelbrot DA, Boussiotis VA, Sharpe AH. CTLA-4 regulates
cell cycle progression during a primary immune response. Eur J
Immunol. 2002;32(2):366–73. doi:10.1002/1521-4141(200202)
32:2\366:AID-IMMU366[3.0.CO;2-5.
22. Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka
I. CTLA-4 overexpression in CD19?/CD5? cells correlates with
the level of cell cycle regulators and disease progression in
B-CLL patients. Leukemia. 2005;19(2):301–4. doi:10.1038/sj.
leu.2403588.
23. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Acti-
vation of human B cells by phosphorothioate oligodeoxynu-
cleotides. J Clin Invest. 1996;98(5):1119–29. doi:10.1172/JCI11
8894.
bFig. 8 Representative examples of flow cytometric analysis of the
effect of CTLA-4 blockade on expression of G0/G1 phase regulators
in normal B lymphocytes after 24 h (a) and 72 h (b) of blocking
culture. Numbers on dot plots represent the percentage of normal B
lymphocytes expressing cyclin D2, cyclin D3 or p27KIP1
Clin Exp Med (2016) 16:317–332 331
123
24. Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB,
Wagner H, Peschel C. Immunostimulatory CpG-oligonucleotides
induce functional high affinity IL-2 receptors on B-CLL cells:
costimulation with IL-2 results in a highly immunogenic phe-
notype. Exp Hematol. 2000;28(5):558–68.
25. Alegre ML, Shiels H, Thompson CB, Gajewski TF. Expression
and function of CTLA-4 in Th1 and Th2 cells. J Immunol.
1998;161(7):3347–56.
26. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler
RS. Intracellular trafficking of CTLA-4 and focal localization
towards sites of TCR engagement. Immunity. 1996;4(6):535–43.
27. Kuiper HM, Brouwer M, Linsley PS, van Lier RA. Activated T
cells can induce high levels of CTLA-4 expression on B cells.
J Immunol. 1995;155(4):1776–83.
28. Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds
PJ, Lombard DB, Freeman GJ, Nadler LM, Gray GS, Thompson CB,
June CH. Characterization of CTLA-4 structure and expression on
human T cells. J Immunol. 1993;151(7):3489–99.
29. De TD, Reato G, Mauro F, Cignetti A, Ferrini S, Guarini A,
Gobbi M, Grossi CE, Foa R. IL4 production and increased CD30
expression by a unique CD8? T-cell subset in B-cell chronic
lymphocytic leukaemia. Br J Haematol. 1999;104(3):589–99.
30. Mu X, Kay NE, Gosland MP, Jennings CD. Analysis of blood
T-cell cytokine expression in B-chronic lymphocytic leukaemia:
evidence for increased levels of cytoplasmic IL-4 in resting and
activated CD8 T cells. Br J Haematol. 1997;96(4):733–5.
31. Rossmann ED, Lewin N, Jeddi-Tehrani M, Osterborg A, Mell-
stedt H. Intracellular T cell cytokines in patients with B cell
chronic lymphocytic leukaemia (B-CLL). Eur J Haematol.
2002;68(5):299–306.
32. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS.
Chronic lymphocytic leukemia B cells are resistant to the apop-
totic effects of transforming growth factor-beta. Blood.
1997;89(3):941–7.
33. Trentin L, Zambello R, Agostini C, Siviero F, Adami F, Mar-
colongo R, Raimondi R, Chisesi T, Pizzolo G, Semenzato G.
Expression and functional role of tumor necrosis factor receptors
on leukemic cells from patients with type B chronic lympho-
proliferative disorders. Blood. 1993;81(3):752–8.
34. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ,
Sison CP, Allen SL, Kolitz J, Schulman P, Vinciguerra VP,
Budde P, Frey J, Rai KR, Ferrarini M, Chiorazzi N. B-cell
chronic lymphocytic leukemia cells express a surface membrane
phenotype of activated, antigen-experienced B lymphocytes.
Blood. 2002;99(11):4087–93.
35. Kosmaczewska A, Ciszak L, Szteblich A, Laba A, Wojtowicz M,
Wolowiec D, Frydecka I. Is cyclin D2 a marker of B-cLL cell
activation? Oncol Res. 2009;18(2–3):127–31.
36. Wolowiec D, Ciszak L, Kosmaczewska A, Bocko D, Teodor-
owska R, Frydecka I, Kuliczkowski K. Cell cycle regulatory
proteins and apoptosis in B-cell chronic lymphocytic leukemia.
Haematologica. 2001;86(12):1296–304.
37. Suwalska K, Pawlak E, Karabon L, Tomkiewicz A, Dobosz T,
Urbaniak-Kujda D, Kuliczkowski K, Wolowiec D, Jedynak A,
Frydecka I. Association studies of CTLA-4, CD28, and ICOS
gene polymorphisms with B-cell chronic lymphocytic leukemia
in the Polish population. Hum Immunol. 2008;69(3):193–201.
doi:10.1016/j.humimm.2008.01.014.
38. Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy
JD, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose
JM, Joshi SS. ATM, CTLA4, MNDA, and HEM1 in high versus
low CD38 expressing B-cell chronic lymphocytic leukemia. Clin
Cancer Res. 2007;13(18 Pt 1):5295–304. doi:10.1158/1078-0432.
CCR-07-0283.
39. Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T.
Sensitization of B-cell chronic lymphocytic leukemia cells to
recombinant immunotoxin by immunostimulatory phosphoroth-
ioate oligodeoxynucleotides. Blood. 2002;99(4):1320–6.
40. Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, Decker
T. Cycling B-CLL cells are highly susceptible to inhibition of the
proteasome: involvement of p27, early D-type cyclins, Bax, and
caspase-dependent and -independent pathways. Exp Hematol.
2003;31(3):218–25.
41. Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J,
Peschel C. Cell cycle progression of chronic lymphocytic leu-
kemia cells is controlled by cyclin D2, cyclin D3, cyclin-de-
pendent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia.
2002;16(3):327–34. doi:10.1038/sj.leu.2402389.
42. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Sch-
neller F, Peschel C. Rapamycin-induced G1 arrest in cycling
B-CLL cells is associated with reduced expression of cyclin D3,
cyclin E, cyclin A, and survivin. Blood. 2003;101(1):278–85.
doi:10.1182/blood-2002-01-0189.
43. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M,
Chiusolo P, Sica S, Leone G, Efremov DG. The Akt signaling
pathway determines the different proliferative capacity of chronic
lymphocytic leukemia B-cells from patients with progressive and
stable disease. Leukemia. 2007;21(1):110–20. doi:10.1038/sj.leu.
2404417.
44. Erlanson M, Landberg G. Prognostic implications of p27 and
cyclin E protein contents in malignant lymphomas. Leuk Lym-
phoma. 2001;40(5–6):461–70. doi:10.3109/10428190109097645.
45. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchen-
baum-Cymbalista F. Prognostic significance of the cell cycle
inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia.
Blood. 1998;91(12):4694–700.
46. Wolowiec D, Wojtowicz M, Ciszak L, Kosmaczewska A, Fry-
decka I, Potoczek S, Urbaniak-Kujda D, Kapelko-Slowik K,
Kuliczkowski K. High intracellular content of cyclin-dependent
kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell
chronic lymphocytic leukemia lymphocytes predicts rapid pro-
gression of the disease. Eur J Haematol. 2009;82(4):260–6.
doi:10.1111/j.1600-0609.2008.01196.x.
47. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S,
Faussat AM, Marie JP, Zittoun R. Overexpression of cyclin D2 in
chronic B-cell malignancies. Blood. 1995;85(10):2870–6.
48. Chiles TC. Regulation and function of cyclin D2 in B lymphocyte
subsets. J Immunol. 2004;173(5):2901–7.
49. Liang J, Slingerland JM. Multiple roles of the PI3 K/PKB (Akt)
pathway in cell cycle progression. Cell Cycle. 2003;2(4):339–45.
50. Schneider H, Valk E, Leung R, Rudd CE. CTLA-4 activation of
phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B
(PKB/AKT) sustains T-cell anergy without cell death. PLoS
ONE. 2008;3(12):e3842. doi:10.1371/journal.pone.0003842.
332 Clin Exp Med (2016) 16:317–332
123
